Register below for this webinar on psychedelic therapies used to treat mood disorders on Tuesday, April 23, 2024, at 1 pm ET. Sign up and receive the free webinar replay link as well!
Not available April 23? Don’t worry. Register now and we’ll send you the replay link to watch at your convenience.
The therapeutic potential of psychedelic drugs for treatment-resistant conditions including mood disorders has sparked renewed interest among researchers, psychiatrists, and patients. New research and ongoing clinical trials are shedding light on the safety and efficacy of these substances, used in controlled therapeutic settings, for conditions that have been challenging to treat using conventional methods. A growing body of research indicates that several classical psychedelics and “psychedelic-like” compounds (e.g. psilocybin, ketamine, MDMA, and LSD) have shown promise for the treatment of substance use disorders, post-traumatic stress disorder (PTSD), anxiety disorders, and treatment-resistant depression (TRD). Some psychedelic treatments, such as MDMA-assisted psychotherapy for PTSD, are currently undergoing phase 3 clinical trials, indicating a significant level of scientific and medical interest in their potential therapeutic applications.
In this webinar, you will learn about:
Have a question for our expert? There will be an opportunity to post questions for the presenter during the live webinar.
Adrian Jacques H. Ambrose, M.D., MPH, MBA, FAPA, is the Senior Medical Director at ColumbiaDoctors Psychiatry at Columbia University Irving Medical Center. For over a decade, Dr. Ambrose has also served as a senior consultant in designing national and global programming in strategy, management, and operations implementation for mid-to-large-sized entities, including Fortune 500 companies. In addition, he specializes in cultivating psychological safety, team building, and culture acceleration for senior managers and executives.
Clinically, Dr. Ambrose specializes in treatment-refractory mood disorders for both the adult, child, and adolescent populations in interventional and novel therapeutics, such as neuronavigated TMS, ketamine, and psychedelics.
Dr. Ambrose completed his medical training at Dartmouth and MGH/McLean Hospital, and value-based healthcare training at the Dartmouth Institute for Health Policy. He also completed the Minority Health Policy Fellowship at Harvard Medical School.
Certificate of Attendance: For information on how to purchase the certificate of attendance option (cost $10), register for the webinar, then look for instructions in the email you’ll receive one hour after it ends. The certificate of attendance link will also be available here, on the webinar replay page, several hours after the live webinar. ADDitude does not offer CEU credits.
Closed captions available.
Tags:
ADDitude collaborates closely with leading medical experts to publish accurate, clear, and authoritative content that millions of readers trust and share.
Since 1998, millions of parents and adults have trusted ADDitude’s expert guidance and support for living better with ADHD and its related mental health conditions. Our mission is to be your trusted advisor, an unwavering source of understanding and guidance along the path to wellness.
It appears JavaScript is disabled in your browser. Please enable JavaScript and refresh the page in order to complete this form.
Get a free issue and free ADDitude eBook, plus save 42% off the cover price.
Psychedelic Therapy for Mood Disorders: Ketamine, MDMA, LSD – ADDitude magazine
